Form 4: MaxCyte Director John Johnston Acquires Shares and Options in Annual Equity Grant

Director John Johnston acquired shares and options in MaxCyte, Inc. as part of the company's Equity Grant Policy for non-employee directors.

Summary

• On June 11, 2024, John Joseph Johnston, a director of MaxCyte, Inc. (MXCT), acquired 21,367 shares of common stock and options for 40,701 shares.
• The acquisition of common stock was in the form of restricted stock units (RSUs), each representing a right to receive one share of MaxCyte's common stock.
• The options have an exercise price of $4.68 and expire on June 10, 2034.
• The shares and options were granted pursuant to MaxCyte's Equity Grant Policy for non-employee directors.
• The shares underlying the grant vest on June 11, 2025, contingent upon Johnston's continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant, which is generally viewed positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The equity grant aligns the director's interests with those of the shareholders.
• The vesting period encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted equity.

Industry Context

Equity grants to non-employee directors are a common practice to incentivize and align their interests with the company's long-term performance. This is a standard component of director compensation packages in publicly traded companies.

Comparison to Industry Standards

• Equity grants to non-employee directors are a standard practice across the biotechnology industry.
• Companies like CRISPR Therapeutics and Editas Medicine also provide similar equity-based compensation to their directors.
• The size and vesting schedule of the grant are generally benchmarked against peer companies to ensure competitiveness and alignment with industry norms.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The vesting schedule encourages the director's continued service, which can benefit the company and its stakeholders.

Key Dates